Poor treatment adherence is problematic in many therapy areas, including multiple sclerosis (MS). Several immunomodulatory drugs are available for the treatment of MS, all of which require frequent parenteral administration. Current first-line therapies are two formulations of interferon (IFN) beta-1a, one of IFN beta-1b, and one of glatiramer acetate. Discontinuation of treatment is common, pa...

BACKGROUND Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal loss. The etiology of MS is unknown; however, environmental and genetic factors play a key role in the development of MS. Diagnostic criteria have been adapted to facilitate earlier diagnosis with increased sensitivity and specificity. Our understanding of...

BACKGROUND/AIM Uric acid was successfully used in both, prevention and treatment of the animal model of multiple sclerosis (MS). Recently it has been shown that inosine, a ribosylated precursor of uric acid, might be used to elevate serum uric acid levels in MS patients. The aim of this study was to evaluate the safety and efficacy of oral inosine as a single drug treatment in patients with MS....

Multiple sclerosis is a debilitating disease of the central nervous system. It affects people of all ages but is more prevalent among 20-40 year olds. Patients with MS can be presented with potentially any neurological symptom depending on the location of the lesion. A quarter of patients with MS suffer from bilateral lower limb spasticity among other symptoms. These devastating effects can be ...

Optic neuritis an inflammatory disorder of the optic nerve inflammation is usually in young’s with symptoms of eye pain and vision loss that occurs is a common symptom of MS. Optic neuritis is one of the first symptoms of MS that observable into disorders in white matter of cerebral cortex. The risk of MS in patients with optic neuritis during 2 years 20% in 15 years, 45-80% is calculated...

Radioembolization (RE) with glass microspheres (MS) loaded Yttrium-90 (90Y) has been used to treat tumors in the liver some reported success. However, assessing absorbed doses (AD) planning tumor volume (PTV) and normal (NLV) is a key problem address RE. In clinical practice, computation of 90Y activity be administered follows manufacturer’s recommendations, which do not consider specific chara...

BACKGROUND Chronic cerebrospinal venous insufficiency (CCSVI) has recently been introduced as a chronic state of impaired cerebral or cervical venous drainage that may be causally implicated in multiple sclerosis (MS) pathogenesis. Moreover, percutaneous transluminal angioplasty of extracranial veins termed "Liberation treatment" has been proposed (based on nonrandomized data) as an alternative...

BACKGROUND Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyzed. METHODS A retrospective claims database analysis was conducted including MS patients who init...